Article By:
ChinaBio® Today
Saturday, November 19, 2022 2:00 PM EDT
Fosun Pharma announced it has licensed US rights to a PD-1 candidate from Henlius Biotech in an $840 million agreement. Meanwhile, Tenacia Biotechnology in-licensed greater China rights to a seizure therapy from Philadelphia’s Marinus Pharma.
In this article: 2696.HK, 2196.HK Also: 002019.SZ, MRNS, 1952.HK, 3692.HK, 2096.HK, 2269.HK, IDIA.SW